SEPTEMBER 14, 2021—Lurbinectedin received approval from the Therapeutic Goods Administration (TGA) as treatment for patients with metastatic SCLC who experienced disease progression during or after receipt of platinum-based chemotherapy. The […] Read more
SEPTEMBER 14, 2021—Health Canada approved sotorasib for second-line treatment of patients with locally advanced or metastatic NSCLC and a KRAS G12C mutation. A Notice of Compliance with Conditions was granted […] Read more
Mario Lacouture, MD, is director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center and specializes in the dermatologic side effects of cancer treatment. He is the founder of the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary program bringing together pat... Read more
Not all published papers are on equal footing. Read more
Surgery has long been the gold standard for diagnosis and management of early-stage operable lung cancer. For patients with inoperable disease or more extensive disease, however, alternative approaches are emerging. […] Read more
Prof. Fabrice Barlesi has been appointed as chief executive officer of Gustave Roussy for a term of 5 years. Prof. Barlesi has been medical director and clinical research director there […] Read more
David R. Gandara, MD, has been appointed chief medical officer (CMO) of the International Society for liquid biopsy (ISLB), an international nonprofit organization dedicated to advancing the field of liquid […] Read more
The International Association for the Study of Lung Cancer (IASLC)—as an international organization of lung cancer experts who serves patients in both developed and developing countries, as well as vulnerable […] Read more